 Indoles
"Indoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Benzopyrroles with the nitrogen at the number one carbon adjacent to the benzyl portion, in contrast to ISOINDOLES which have the nitrogen away from the six-membered ring.
| Descriptor ID |
D007211
|
| MeSH Number(s) |
D03.633.100.473
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Indoles".
Below are MeSH descriptors whose meaning is more specific than "Indoles".
This graph shows the total number of publications written about "Indoles" by people in this website by year, and whether "Indoles" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 3 | 1 | 4 | | 1997 | 2 | 4 | 6 | | 1998 | 0 | 1 | 1 | | 1999 | 1 | 1 | 2 | | 2000 | 1 | 3 | 4 | | 2001 | 2 | 3 | 5 | | 2002 | 1 | 2 | 3 | | 2003 | 0 | 3 | 3 | | 2004 | 1 | 5 | 6 | | 2005 | 1 | 3 | 4 | | 2006 | 2 | 2 | 4 | | 2007 | 5 | 7 | 12 | | 2008 | 3 | 4 | 7 | | 2009 | 3 | 7 | 10 | | 2010 | 1 | 2 | 3 | | 2011 | 3 | 7 | 10 | | 2012 | 6 | 12 | 18 | | 2013 | 8 | 10 | 18 | | 2014 | 12 | 9 | 21 | | 2015 | 11 | 11 | 22 | | 2016 | 7 | 2 | 9 | | 2017 | 9 | 7 | 16 | | 2018 | 8 | 4 | 12 | | 2019 | 6 | 10 | 16 | | 2020 | 2 | 6 | 8 | | 2021 | 8 | 7 | 15 | | 2022 | 0 | 10 | 10 | | 2023 | 2 | 13 | 15 | | 2024 | 12 | 12 | 24 | | 2025 | 17 | 8 | 25 | | 2026 | 3 | 1 | 4 |
To return to the timeline, click here.
Below are the most recent publications written about "Indoles" by people in Profiles.
-
Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, Morgan SJ, Singh PK, Nichols DP, Kelly A, Solomon GM. Long-term reductions in inflammation in people with cystic fibrosis treated with elexacaftor/tezacaftor/ivacaftor. Ann Am Thorac Soc. 2026 Feb 01; 23(2):241-251.
-
Abi-Aad SJ, Tsalatsanis A, Narkewicz M, Leung DH, Khalaf RT. The Impact of Elexacaftor-Tezacaftor-Ivacaftor on Biochemical Surrogates of Cystic Fibrosis Hepatobiliary Involvement: A Retrospective Cohort Study. Pediatr Pulmonol. 2026 Feb; 61(2):e71522.
-
Castellani C, Mondejar-Lopez P, Van Goor F, Quon BS, Alghisi F, Fabrizzi B, Ramsey B, Taylor-Cousar JL, McKone EF, Tullis E, Weinstock TG, Tan V, Ahluwalia N, Mahic M, Liu L, Saayman S, Altshuler D, Waltz D, Mall MA, Fajac I. Elexacaftor/tezacaftor/ivacaftor for cystic fibrosis and rare CFTR variants: in vitro translation to a phase 3, double-blind, randomized, placebo-controlled trial, and real-world study. Am J Respir Crit Care Med. 2026 Feb 01; 212(2):327-337.
-
Liu CM, Fischer JL, Overdevest JB, Zemke AC, Strand MJ, Gudis DA, Kimple AJ, Tervo JP, DiMango E, Goralski JL, Keating C, Senior B, Stapleton AL, Taylor-Cousar JL, Beswick DM. Psychometric validity of the 22-item sinonasal outcome test in cystic fibrosis. J Cyst Fibros. 2026 Mar; 25(2):353-358.
-
Mandala A, Undi RB, Janssen RC, Sugino KY, Zhao W, Nelson BN, Teague AM, Patil NY, Zemsky Berry K, Varshney R, Bergman BC, Rudolph MC, Joshi AD, Rajala RVS, Jonscher KR, Friedman JE. Reprogramming offspring liver health: maternal indole supplementation as a preventive strategy against MASLD. EBioMedicine. 2026 Jan; 123:106098.
-
Lyons ER, Vigers T, Simoni M, Lynn C, Muther E. Body Image Perceptions and Elexacaftor/Tezacaftor/Ivacaftor (ETI) Use in Adolescents and Young Adults Living With Cystic Fibrosis. Pediatr Pulmonol. 2025 Dec; 60(12):e71418.
-
Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F. Elexacaftor/tezacaftor/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros. 2026 May; 25(3):450-456.
-
Ye W, Magee JC, Huang S, Leung DH, Bozic M, Stoll J, C Ling S, Paranjape SM, Karnsakul W, Jay Freeman A, Schwarzenberg SJ, Palermo J, Alonso E, Green N, Masand P, Karmazyn B, Harned R, Navarro OM, Siegel MJ, Towbin A, Alazraki A, Otto RK, Nicholas JL, Narkewicz MR. Impact of elexacaftor/tezacaftor/ivacaftor on biomarkers of cystic fibrosis hepatobiliary involvement in the PUSH study. J Pediatr Gastroenterol Nutr. 2026 Feb; 82(2):350-357.
-
Knoll RL, Brauny MM, Robert E, Cloos L, Waser L, Hilbert K, Ulmer N, Hillen B, Birkner T, Bartolomaeus TUP, Nitsche O, Jarquín-Díaz VH, Lynch S, Gehring S, Maier L, Poplawska K, Forslund-Startceva SK. CFTR modulator therapy drives microbiome restructuring through improved host physiology in cystic fibrosis: the IMMProveCF phase IV trial. Nat Commun. 2025 Nov 18; 16(1):10111.
-
Vladar EK, Gillen AE, Yadav S, Murphree MR, Baraghoshi D, Harris JK, Pruesse E, Niemiec SS, Wilson AW, Hisert KB, Humphries SM, Strand M, Lynch DA, Seibold MA, Beswick DM, Taylor-Cousar JL. Transcriptomic and functional responses of the cystic fibrosis airway epithelium to CFTR modulator therapy. JCI Insight. 2025 Nov 10; 10(21).
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|